BACKGROUND: Myeloma occurs disproportionately in African Americans, with disparities in outcomes potentially caused by access to care, cytogenetics, and immunity. A gap in knowledge of immune function dissimilarities between African Americans and whites exists. Data for other diseases suggest innate differences in immunity and inflammatory markers, with potential implications for therapeutic monoclonal antibodies reliant on secondary immune activation for activity. METHODS: Patients receiving daratumumab or elotuzumab, lenalidomide, and dexamethasone were retrospectively studied with a primary endpoint of response at 2 (daratumumab) or 4 months (elotuzumab). Secondary endpoints included stable disease or better at the same points, treatment duration, time to best response, and adverse events. RESULTS: Eighty patients were included; baseline characteristics were balanced with the exception of the stage at diagnosis, which was more advanced in African Americans. No statistically significant difference in response was seen: 37.9% in whites versus 11.8% in African Americans with daratumumab (P = .090) and 60% in whites versus 44% in African Americans with elotuzumab (P = .462). There were no differences in the duration of treatment, the time to best response, or adverse events. Common potential immune-related adverse events in both arms were fatigue (39%), back pain (30%), and infusion reactions (40%). Anemia was significantly associated with a response to daratumumab (P = .02); no patients without anemia responded at 2 months, whereas 34.4% of patients with anemia did. CONCLUSIONS: No significant difference in response, duration of treatment, or time to response was seen by race, although a trend toward greater early response rates in whites was observed. In these cohorts, as in other analyses, African American patients tended to present with later stage disease. Cancer 2018;124: 4358-4365.
INTRODUCTION
Multiple myeloma is a plasma cell malignancy estimated to account for approximately 30,000 new cases of cancer in the United States in 2018. 1 It occurs disproportionately in African American patients, who have an incidence double that of other groups, and the annual incidence is 27.2 per 100,000 in African Americans and 12.2 per 100,000 in whites. Over the past several years, there have been significant improvements in the treatment of myeloma with the approval of novel agents and combinations, including proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) and immunomodulatory drugs (lenalidomide, thalidomide, and pomalidomide) combined with autologous stem cell transplantation. The addition of these agents has increased 5-year survival rates from 25% to 49.6%. 1, 2 However, in patients with relapsed disease refractory to these therapies, outcomes remain poor with a median overall survival of 9 months for those younger than 65 years and a median overall survival of 6.7 months for those 65 years or older, and treatment options are more limited. [2] [3] [4] In 2015, the Food and Drug Administration approved 2 first-in-class agents, daratumumab and elotuzumab, for the treatment of relapsed, refractory multiple myeloma. Daratumumab and elotuzumab are monoclonal antibodies targeting CD38 and signaling lymphocytic activation molecule family member 7 (SLAMF7), respectively, markers that are highly expressed on myeloma cells. 5 Daratumumab was initially approved as a single agent for patients who have received 3 or more prior therapies, including a proteasome inhibitor and an immunomodulatory drug, or who are double-refractory to these drugs. It is targeted to CD38 and induces apoptosis directly and by immune-mediated tumor cell lysis through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis. For patients who respond to daratumumab alone, median progression-free survival is 15
Cancer November 15, 2018 months. 6 Elotuzumab is indicated in combination with lenalidomide and dexamethasone for patients who have received 1 to 3 prior therapies and, through inhibition of SLAMF7, leads to activation of natural killer cells and mediates antibody-dependent cell-mediated cytotoxicity. Median progression-free survival in patients treated with combination therapy was shown to be 19.4 months in a phase 3 trial. 7 Despite substantial improvements in therapy, outcomes for African American patients may continue to be inferior. Waxman et al 8 conducted a retrospective population-based study in 2010, including 5798 African American patients and 28,939 white patients, that looked at racial disparities and their effects on outcomes, including incidence, disease-specific survival, and relative survival rates. They found that, for whites, 5-year relative survival rates increased significantly from 1973-1993 to 1994-1998 (from 26.3% to 30.8%; P < .001) and from 1994-1998 to 1999-2005 (from 30.8% to 35.0%; P = .004). Survival improvements among African Americans were smaller and not statistically significant (from 31.0% in 1973-1993 to 34.1% in 1999-2005; P = .07). A number of causes of this disproportionality, including differences in access to medical care and treatment, cytogenetics, and immunity, have been suggested. 9 There is a lack of data on multiple myeloma concerning baseline immune function categorized by race. However, a number of investigations in other diseases in which immunity plays a large role have been conducted, and differences have been demonstrated. Ness et al 10 evaluated the race-specific distribution of allelic variants in cytokine genes known to stimulate inflammation. Their group found that cytokine genotypes upregulating inflammatory responses were more common in African American women than their white counterparts. Similarly, Standish et al 11 evaluated African American patients with breast cancer and showed increased expression of proinflammatory cytokine genotypes correlating with elevations in interleukin 1 (IL-1) and IL-6, which was 36.5 times more commonly expressed in comparison with whites, and decreased expression of immunosuppressant cytokine genotypes, specifically IL-10. This finding correlated with a higher mortality rate as well as a greater risk of inflammatory breast cancer in African American patients. Hoffmann et al 12 evaluated the differential racial distribution of allelic variants in cytokine genes and its effect on allograft outcomes in transplant patients. They observed significant differences in the distribution of the polymorphic alleles for IL-2 and the inheritance of IL-6 alleles and IL-10 genotypes that resulted in high expression in African Americans in comparison with whites.
On the basis of these data, there may potentially be an innate difference in immune responses between African American and white patients with myeloma caused by the upregulation of inflammatory markers in African Americans. This may lead to differences in responses to therapies, disease progression, and adverse events. Responses to monoclonal antibody therapy such as daratumumab and elotuzumab may be augmented in African American patients because of their mechanisms of action if innate immunity confers greater reactivity to these agents. Similarly, adverse events attributable to immune-based interventions may be greater. Because African American patients composed only 14% and 4% of patients in daratumumab and elotuzumab clinical trials, respectively, we aimed to evaluate potential racebased differences in the Emory population with respect to single-agent daratumumab and elotuzumab, lenalidomide, and dexamethasone therapy in African American and white patients. 
MATERIALS AND METHODS

Study Design and Patient Selection
This was an institutional review board-approved, single-institution, retrospective case study. Eligible patients were identified through pharmacy and investigational records and were 18 years old or older, had a known diagnosis of myeloma, and had received singleagent daratumumab or a combination of elotuzumab, lenalidomide, and dexamethasone between January 1, 2009, and July 31, 2016. Patients were excluded if they had received daratumumab in combination with other agents, had received elotuzumab with any other combination of therapies other than lenalidomide and dexamethasone, or if they had a diagnosis of smoldering myeloma.
Outcome Measures
The primary endpoint was the overall response rate at 2 months for daratumumab and at 4 months for elotuzumab. Responses were evaluated with the International Myeloma Working Group criteria.
14 Secondary endpoints were the duration of treatment, which was defined as the time from the date of the first treatment to the date of the last treatment, and the time to best response. Safety was also evaluated and included the collection of treatment-emergent adverse events of any grade based on the Common Terminology Criteria for Adverse Events
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Statistical Analysis
Descriptive statistics (proportions for categorical variables and means and standard deviations or medians for continuous variables) were used for demographic, outcome, and safety data. A chi-square test and Fisher's exact test were performed for the categorical univariate analysis if appropriate. A t test and a Kruskal-Wallis test were performed for the numerical covariate univariate analysis. Multiple binary logistic regression was fit by a backward variable selection method with an α = .20 removal criterion. The significance levels were set at .05 for all tests.
RESULTS
Patient Characteristics
A total of 80 patients were included in this study, and they were split into 2 arms (46 patients in the daratumumab arm and 34 patients in the elotuzumab arm). In the daratumumab arm, 17 patients were African American, and 29 patients were white. For elotuzumab, 9 were African American, and 25 were white (Fig. 1) . Baseline characteristics were balanced between the 2 study groups in both arms with the exception of the stage at diagnosis (Tables 1 and 2 ). In the daratumumab arm, African Americans were significantly more likely to have a multiple myeloma type of immunoglobulin G than white patients (82% vs 55%; P = .044). More white patients (59%) presented with stage I disease than African American patients (24%; P = .013). In the elotuzumab arm, similar results were seen, with 48% and 11%, respectively, presenting with stage I disease (P = .048). Baseline allergies in the elotuzumab arm were also higher in the white group (55%) than the African American group (P = .047). There was no statistically significant difference in the arms between whites and African Americans with respect to the presence of high-risk cytogenetics, the number of lines of prior therapy, or baseline allergies.
Primary and Secondary Outcomes
In the daratumumab arm (Table 3) , a partial response or better at 2 months was seen in 13 of the 46 patients overall (28%): 11 whites and 2 African Americans. The rate of stable disease or better at 2 months was 72.4% for whites and 64.7% for African Americans (P = .583). The mean duration of treatment was 141 days (range, 20-684 
Cancer November 15, 2018 days) and 119 days (range, 20-367 days), respectively. (P = .549). The mean time to best response was 70 days in the white group and 56 days in the African American group (P = .383). Statistical analysis showed no difference in the response rate, duration of treatment, or time to best response between whites and African Americans.
In the elotuzumab arm (Table 4) , there were no statistically significant differences in the response rate, duration of treatment, or time to best response between whites and African Americans, with the 2 groups having similar overall response rates at 4 months (92% vs 89%; P = 1.00). The mean duration of treatment was 606 days (range, 27-2901 days) for the white group and 528 days (range, 41-2243 days) for the African American group (P = .79). The mean time to best response was shorter in the African American group (137 days) than the white group (245 days).
A multivariate analysis was then performed to assess other factors that may have affected response, regardless of race, including the cytogenetic risk, the number of lines of therapy, and the stage at diagnosis, which may suggest more advanced and/or aggressive disease and inferior outcomes. We also assessed for an association of response with exploratory factors such as the baseline allergy status or the presence of infusion reactions. Responses were noted in both arms regardless of factors such as race, sex, stage at diagnosis, immunoglobulin-type multiple myeloma, high-risk cytogenetics, or adverse events, with the exception of anemia in the daratumumab arm (Table 5) . There was an association seen between anemia and a response to daratumumab (P = .02); no patients without anemia achieved an overall response at 2 months, whereas 34.4% of patients with anemia, independently of race, did achieve a response (Table 5) . 
Adverse Events
Adverse events were compared between whites and African American in the 2 arms and are reported in Table 6 . There was no significant difference in toxicity in the daratumumab arm, including the rate/severity of grade 1/2 infusion reactions: the rate was 44.8% in whites and 47.1% in African Americans (P = .883). African Americans had a significantly higher probability of having back pain of any grade during elotuzumab treatment than whites (P = .017). There were no other significant differences in rates of toxicities between the 2 groups, including grade 1/2 infusion reactions, which occurred at a rate of 32% in the white group and at a rate of 33% in the African American group (P = 1.00). There were no grade 3/4 infusion reactions to either agent. The most common adverse events of any grade in patients across both arms were fatigue (39%), back pain (30%), and infusion reactions (40%).
DISCUSSION
We aimed to evaluate potential differences in responses to monoclonal antibody therapy between African American patients and white patients on the basis of associations between innate immunity and clinical differences in other diseases. To our knowledge, this is the first comparison of this kind in patients with myeloma receiving daratumumab and elotuzumab. Response rates at 2 months for single-agent daratumumab and at 4 months for a combination of elotuzumab, lenalidomide, and dexamethasone did not show any significant differences between the 2 racial groups. There were also no differences in baseline allergies or infusion reactions, both of which may be viewed as immune surrogates.
The study populations had a global distribution similar to those seen in clinical trials, particularly with respect to age, previous lines of treatment, and highrisk cytogenetics. These characteristics were also similar between races in both arms in our study. The phase 2 SIRIUS study, which evaluated single-agent daratumumab in patients with multiple myeloma, included 84 whites (79%) and 15 African Americans (14%). In the daratumumab arm in our study, 63% of the patients were white, and 37% of the patients were African American. 13 We had a greater proportion of African American patients in our study in comparison with the SIRIUS study, which represented the typical population distribution in our metropolitan area of Atlanta and made this an appropriate site for comparing race-associated differences in response. The presenting stage at diagnosis significantly varied in our study by race. In the white group, 59% of patients presented with stage I disease, whereas only 24% did in the African American group. Similar results were seen in the elotuzumab arm, with 48% of white patients but only 11% in the African American group presenting with stage I disease. This finding conforms with the literature, which has shown that African American patients typically present at later stages. 15, 16 This finding has also been observed for cancers other than myeloma, and a number of factors have been hypothesized as sources of this disproportionality, including socioeconomic status and access to medical care. 15 In our study, we did not evaluate patients' socioeconomic status in relation to their stage at diagnosis or their response to therapy.
The results seen in both the daratumumab and elotuzumab arms are similar to those of clinical trials. In the daratumumab arm, response rates were not statistically Cancer November 15, 2018 different between whites and African Americans at 2 months of treatment. In the SIRIUS study, response rates were also similar between whites (27.3%) and African Americans (29.8%). We chose 2 months as the time for evaluating responses on the basis of the SIRIUS trial, in which the time to response was typically 1 month and ranged from 0.9 to 5.6 months, and patients had a progression-free survival time of approximately 3.7 months. In our study, patients were typically on treatment for an average of 4.3 months, which was comparable to the treatment time seen in the SIRIUS study. Similarly, in the elotuzumab arm, similar response rates were seen in African American and white patients at 4 months; this time was chosen on the basis of the ELOQUENT-2 study, which evaluated elotuzumab plus lenalidomide and dexamethasone in patients with multiple myeloma. 7 In this study, the median time to response was 2.8 months. The median duration of response in the ELOQUENT-2 study was 19.4 months, which was similar to the duration in our study, which showed a median duration of 18.9 months.
On the basis of these results, a univariate analysis was performed to assess the relation of multiple variables other than race to response. There were no significant differences found, with the lone exception of anemia in the daratumumab arm, which showed a possible relation The bolded value is significant.
Cancer November 15, 2018 to a response to therapy. In the subset of 14 patients who did not respond to treatment (30%), none had anemia either at the baseline or on therapy. Conversely, among the 32 patients who responded to treatment, 34.4% had anemia at some time during their treatment. Anemia is common in patients with multiple myeloma and is one of the CRAB criteria (ie, calcium [elevated], renal failure, anemia, and bone lesions). 17 In addition, it is present at diagnosis in 67% of patients, is more common in patients with recurrent or progressive disease, and has been shown to be a poor prognostic factor for outcomes. [18] [19] [20] [21] In our analysis, patients who did not respond did not have anemia, and this suggests that the response to single-agent daratumumab may be more robust in those with more advanced disease, a finding previously unreported. Treatment-emergent anemia is common with myeloma treatment; however, patients may safely receive red cell transfusions concurrently with daratumumab. It did not increase the overall rate of anemia when it was added to bortezomib or lenalidomide, and fewer patients had grade 3 or 4 anemia with the addition of daratumumab in comparison with lenalidomide alone (12.4% vs 19.6%); this reflected disease activity. [22] [23] [24] Daratumumab binds to CD38 and induces CD38 loss on red blood cells, and patients must either be typed and screened for red cell transfusions before treatment or use a commercial assay for antibody removal because of the formation of anti-red blood cell antibodies. 25 Although anemia management and mechanisms are more complicated in patients receiving daratumumab, its absence before treatment may be a predictor of a lower likelihood of response; however, our data alone are not sufficient to make a clear association, and additional study is required to further analyze the effect of anemia on responses to therapy.
Both daratumumab and elotuzumab were well tolerated, and they had adverse event rates and severities in our population similar to those in their respective clinical trials. The most common adverse events in both groups were fatigue, anemia, and back pain, and this was similar to the SIRIUS study (fatigue and anemia) and the ELOQUENT-2 trial (neutropenia, fatigue, and pneumonia). There was a higher incidence of back pain seen in the African American group in the elotuzumab arm. This likely represents more advanced disease, which was more prevalent in the African American group in comparison with whites in our study. There was no difference in infusion reaction rates between races in either arm.
Our study has limitations, including the small sample sizes in both arms and between groups, and this makes it challenging to assert definitive conclusions. However, with the exception of a greater African American population, our demographics conformed to historical data in published clinical trials. Some of the data were collected from patients in clinical trials of daratumumab and elotuzumab because we did a chart review from 2009, and both drugs received Food and Drug Administration approval in 2015. This may have affected the study population because patients in clinical trials are typically required to meet more stringent inclusion criteria. This could also have an effect on our reporting and management of adverse effects. Finally, we included only patients on single-agent daratumumab. This drug is now approved for use in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone. This was done to limit the variability in responses in patients on daratumumab and make the group comparable to initial monotherapy clinical trials.
In conclusion, no statistically significant difference was found in the response to monoclonal antibody treatment, the duration of treatment, or the time to response between whites and African Americans. This study aligns with previous observations showing that African American patients present with later stage disease. A possible association between a response to daratumumab and anemia at the baseline can be made on the basis of our results; however, additional analysis and study are needed.
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